Dig Dis 2005;23:56–64
(DOI:10.1159/000084726)

Transjugular Intrahepatic Portosystemic Shunt

Ochs A.
Department of Internal Medicine, Evangelisches Diakonie Krankenhaus, Teaching Hospital of the Medical Faculty, University of Freiburg, Freiburg, Germany
email Corresponding Author


 goto top of outline Key Words

  • Portal hypertension
  • Variceal bleeding
  • Ascites
  • Hepatorenal syndrome
  • TIPS
  • Budd-Chiari syndrome
  • Hepatic hydrothorax
  • Endoscopic band ligation
  • Cirrhosis
  • Hepatic encephalopathy

 goto top of outline Abstract

The transjugular intrahepatic portosystemic shunt (TIPS) is an interventional treatment resulting in decompression of the portal system by creation of a side-to-side portosystemic anastomosis. Since its introduction 16 years ago, more than 1,000 publications have appeared demonstrating broad acceptance and increasing clinical use. This review summarizes our present knowledge about technical aspects and complications, follow-up of patients and indications. A technical success rate near 100% and a low occurrence of complications clearly depend on the skills of the operator. The follow-up of the TIPS patient has to assess shunt patency, liver function, hepatic encephalopathy and the possible development of hepatocellular carcinoma. Shunt patency can best be monitored by duplex sonography and can avoid routine radiological revision. Short-term patency may be improved by anticoagulation, while such a treatment does not influence long-term patency. Stent grafts covered with expanded polytetrafluoroethylene show promising long-term patency comparable with that of surgical shunts. With respect to the indications of TIPS, much is known about treatment of variceal bleeding and refractory ascites. The thirteen randomized studies that are available to date show that survival is comparable in patients receiving TIPS or endoscopic treatment for acute or recurrent variceal bleeding. Another group comprises patients with refractory ascites and related complications, such as hepatorenal syndrome and hepatic hydrothorax. It has been demonstrated that TIPS improves these complications. Five randomized studies comparing TIPS with paracentesis and one study comparing TIPS with the peritoneo-venous shunt showed good response of ascites but controversial results on survival. In addition, TIPS has been successfully applied to patients with Budd-Chiari syndrome, portal vein thrombosis, before liver transplantation, and for the treatment of ectopic variceal bleeding.

Copyright © 2005 S. Karger AG, Basel


 goto top of outline References
  1. Palmaz JC, Sibbitt RR, Reuter SR, Garcia F, Tio FO: Expandable intrahepatic portacaval shunt stents: Early experience in the dog. Am J Roentgenol 1985;145:821–825.
  2. Rösch J, Hanafee W, Snow H, Barenfus M, Gray R: Transjugular intrahepatic portocaval shunt. Am J Surg 1971;121:588–592.
  3. Colapinto RF, Stronell RD, Gildiner M, et al: Formation of intrahepatic portosystemic shunts using a balloon dilatation catheter: Preliminary clinical experience. AJR Am J Roentgenol 1983;140:709–714.
  4. Gutierrez OH, Burgener FA: Production of nonsurgical portosystemic venous shunts in dogs by transjugular approach. Radiology 1979;130:507–509.
  5. Rössle M, Richter GM, Nöldge G, et al: Performance of an intrahepatic portacaval shunt (PCS) using a catheter technique – a case report. Hepatology 1988;8:1348A.

    External Resources

  6. Gschwantler M, Gebauer A, Rohrmoser M, et al: Clinical outcome two years after implantation of a transjugular intrahepatic portosystemic shunt for recurrent variceal bleeding (see comments). Eur J Gastroenterol Hepatol 1997;9:15–20.
  7. Rössle M, Siegerstetter V, Huber M, Ochs A: The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 1998;18:73–89.
  8. Krajina A, Lojik M: TIPS Technique; in Hulek P, Krajina A (eds): Current Practice of TIPS. Hradec Kralove, Olga Stambergova, 2001, pp 56–119.
  9. Haskal ZJ, Martin L, Cardella JF, et al: Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2003;14:S265–S270.

    External Resources

  10. Rössle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K: How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001;96:3379–3383.
  11. Kleber G, Steudel N, Behrmann C, et al: Hepatic arterial flow volume and reserve in patients with cirrhosis: Use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999;116:906–914.
  12. Gülberg V, Haag K, Rössle M, Gerbes AL: Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002;35:630–634.
  13. Walser E, Ozkan OS, Raza S, Soloway R, Gajula L: Hepatic perfusion as a predictor of mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites. J Vasc Interv Radiol 2003;14:1251–1257.
  14. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M: Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743–748.
  15. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H: Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: Preliminary report of a prospective study. Hepatology 1994;19:129–132.
  16. Stanley AJ, Redhead DN, Bouchier IA, Hayes PC: Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis. Am J Gastroenterol 1998;93:2463–2468.
  17. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC: Reduction in renal blood flow following acute increase in the portal pressure: Evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664–670.
  18. Wong F, Sniderman K, Liu P, Blendis LM: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997;112:899–907.
  19. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis LM: Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995;122:816–822.
  20. Ochs A, Rössle M, Haag K, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192–1197.
  21. Tripathi D, Helmy A, Macbeth K, et al: Ten years’ follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Eur J Gastroenterol Hepatol 2004;16:9–18.
  22. Haag K, Ochs A, Deibert P, et al: Hemodynamics, liver function and clinical follow-up after TIPS (German). Radiologe 1994;34:183–186.
  23. Nagele T, Seeger U, Pereira P, et al: MR proton spectroscopy to monitor the concentration changes in cerebral metabolites following a TIPS placement. Röfo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999;170:298–303.
  24. Hauenstein KH, Haag K, Ochs A, Langer M, Rössle M: The reducing stent: Treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995;194:175–179.
  25. Rose SE, Katz MD: Intentional occlusion of a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 1995;18:109–111.
  26. Haskal ZJ, Cope C, Soulen MC, Shlansky-Goldberg RD, Baum RA, Redd DC: Intentional reversible thrombosis of transjugular intrahepatic portosystemic shunts. Radiology 1995;195:485–488.
  27. Haag K, Ochs A, Hauenstein KH, Siegerstetter V, Deibert P, Rössle M: Management of TIPS-induced refractory hepatic encephalopathy. Hepatology 1994;20:111A.
  28. Mamiya Y, Kanazawa H, Kimura Y, et al: Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res 2004;30:162–168.
  29. Chalasani N, Clark WS, Martin LG, et al: Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000;118:138–144.
  30. Brown DB, Fundakowski CE, Lisker-Melman M, et al: Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Intervent Radiol 2004;15:1209–1218.
  31. Schepke M, Roth F, Fimmers R, et al: Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003;98:1167–1174.
  32. Schepke M, Roth F, Koch L, et al: Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003;67:146–153.
  33. Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M: Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004;16:607–612.
  34. Benito A, Bilbao J, Hernandez T, et al: Doppler ultrasound for TIPS: Does it work? Abdom Imaging 2004;29:45–52.
  35. Middleton WD, Teefey SA, Darcy MD: Doppler evaluation of transjugular intrahepatic portosystemic shunts. Ultrasound Q 2003;19:56–70.
  36. Wachsberg RH: Doppler ultrasound evaluation of transjugular intrahepatic portosystemic shunt function: Pitfalls and artifacts. Ultrasound Q 2003;19:139–148.
  37. Murphy TP, Beecham RP, Kim HM, Webb MS, Scola F: Long-term follow-up after TIPS: Use of Doppler velocity criteria for detecting elevation of the portosystemic gradient. J Vasc Interv Radiol 1998;9:275–281.
  38. Zizka J, Elias P, Krajina A, et al: Value of Doppler sonography in revealing transjugular intrahepatic portosystemic shunt malfunction: A 5-year experience in 216 patients. AJR Am J Roentgenol 2000;175:141–148.
  39. Haag K: Color Doppler Imaging of Abdominal Vessels; in Lanzer P, Yoganathan AP (eds): Vascular Imaging by Color Doppler and Magnetic Resonance. Berlin, Springer, 1991, pp 241–265.
  40. Siegerstetter V, Huber M, Ochs A, Blum HE, Rössle M: Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 1999;29:33–38.
  41. Angermayr B, Cejna M, Koenig F, et al: Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003;38:1043–1050.
  42. Hausegger KA, Portugaller H, Macri NP, et al: Covered stents in transjugular portosystemic shunt: healing response to non-porous ePTFE covered stent grafts with and without intraluminal irradiation. Eur Radiol 2003;13:1549–1558.
  43. Cejna M, Peck-Radosavljevic M, Thurnher S, et al: ePTFE-covered stent-grafts for revision of obstructed transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2002;25:365–372.
  44. DiSalle RS, Dolmatch BL: Treatment of TIPS stenosis with ePTFE graft-covered stents. Cardiovasc Intervent Radiol 1998;21:172–175.
  45. Charon JP, Alaeddin FH, Pimpalwar SA, et al: Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2004;15:1219–1230.
  46. Imperiale TF, Teran JC, McCullough AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995;109:1289–1294.
  47. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2001;CD002147.
  48. Sharara AI, Rockey DC: Gastroesophageal variceal hemorrhage. N Engl J Med 2001;345:669–681.
  49. D’Amico G, Pietrosi G, Tarantino I, Pagliaro L: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane meta-analysis. Gastroenterology 2003;124:1277–1291.
  50. Avgerinos A, Armonis A, Manolakopoulos S, et al: Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study. J Hepatol 1997;26:1034–1041.
  51. Gross M, Schiemann U, Muhlhofer A, Zoller WG: Meta-analysis: Efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy 2001;33:737–746.
  52. Burroughs AK, McCormick PA: Prevention of variceal rebleeding. Gastroenterol Clin North Am 1992;21:119–147.
  53. Technology Assessment Status Evaluation – Update: Endoscopic band ligation. November, 1996. ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1998;47:573–575.
  54. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995;123:280–287.
  55. Haag K, Rössle M, Hauenstein KH, et al: Der transjuguläre intrahepatische portosystemische Stent-Shunt (TIPS) in der Notfallbehandlung der portalen Hypertension. Intensivmedizin 1993;30:479–483.
  56. Le Moine O, Deviere J, Ghysels M, et al: Transjugular intrahepatic portosystemic stent shunt as a rescue treatment after sclerotherapy failure in variceal bleeding. Scand J Gastroenterol 1994;207(suppl):23–28.

    External Resources

  57. McCormick PA, Dick R, Panagou EB, et al: Emergency transjugular intrahepatic portosystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. Br J Surg 1994;81:1324–1327.
  58. Jalan R, John TG, Redhead DN, et al: A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage (see comments). Am J Gastroenterol 1995;90:1932–1937.
  59. Sanyal AJ, Freedman AM, Luketic VA, et al: Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138–146.
  60. Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK: ‘Salvage’ transjugular intrahepatic portosystemic shunts: Gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998;114:981–987.
  61. Banares R, Casado M, Rodriguez-Laiz JM, et al: Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol 1998;93:75–79.
  62. Patch D, Nikolopoulou V, McCormick A, et al: Factors related to early mortality after trans-jugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 1998;28:454–460.
  63. Rössle M, Haag K, Ochs A, et al: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165–171.
  64. Burroughs AK, Vangeli M: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: Randomized trials for secondary prophylaxis of variceal bleeding: An updated meta-analysis. Scand J Gastroenterol 2002;37:249–252.
  65. Escorsell A, Banares R, Garcia-Pagan JC, et al: TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385–392.
  66. Norton ID, Andrews JC, Kamath PS: Management of ectopic varices. Hepatology 1998;28:1154–1158.
  67. Ninoi T, Nakamura K, Kaminou T, et al: TIPS versus transcatheter sclerotherapy for gastric varices. AJR Am J Roentgenol 2004;183:369–376.
  68. Rees CJ, Nylander DL, Thompson NP, Rose JD, Record CO, Hudson M: Do gastric and oesophageal varices bleed at different portal pressures and is TIPS an effective treatment? Liver 2000;20:253–256.
  69. Wu CY, Yeh HZ, Chen GH: Pharmacologic efficacy in gastric variceal rebleeding and survival: Including multivariate analysis. J Clin Gastroenterol 2002;35:127–132.
  70. Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA: Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000;118:905–911.
  71. Obideen MK, Wehbi M, Ghazale A, Martinez E, Cai Q: Efficacy and safety of transjugular intrahepatic portosystemic shunt in the treatment of nongastric extraesophageal variceal bleeding. J Clin Gastroenterol 2004;38:373–376.
  72. Illuminati G, Smail A, Azoulay D, Castaing D, Bismuth H: Association of transjugular intrahepatic portosystemic shunt with embolization in the treatment of bleeding duodenal varix refractory to sclerotherapy. Dig Surg 2000;17:398–400.
  73. Runyon BA: Care of patients with ascites. N Engl J Med 1994;330:337–342.
  74. Gines P, Cardenas A, Arroyo V, Rodes J: Management of cirrhosis and ascites. N Engl J Med 2004;350:1646–1654.
  75. Moore KP, Wong F, Gines P, et al: The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258–266.
  76. Arroyo V, Gines P, Gerbes AL, et al: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis (review). International Ascites Club. Hepatology 1996;23:164–176.
  77. Runyon BA: Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997;17:163–173.
  78. Ochs A, Siegerstetter V: TIPS and refractory ascites, hepatorenal syndrome and other complications; in Hulek P, Krajina A (eds): Current Practice of TIPS. Hradec Kralove, Olga Stambergova 2001, pp 133–142.
  79. Peron JM, Barange K, Otal P, et al: Transjugular intrahepatic portosystemic shunts in the treatment of refractory ascites: Results in 48 consecutive patients. J Vasc Intervent Radiol 2000;11:1211–1216.
  80. Nair S, Singh R, Yoselewitz M: Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites. J Vasc Intervent Radiol 2004;15:1431–1434.
  81. Wong W, Liu P, Blendis LM, Wong F: Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 1999;106:315–322.
  82. Jalan R, Redhead DN, Thomas HW, et al: Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 1996;8:1111–1116.
  83. Plauth M, Schutz T, Buckendahl DP, et al: Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. J Hepatol 2004;40:228–233.
  84. Sandokji AM, Chau J, Aghdassi E, Wong F, Blendis LM, Allard JP: Effects of transjugular intrahepatic portosystemic shunt (TIPS) on nutritional status and comparison between methods of measuring fat free mass (FFM) in patients with liver cirrhosis. Gastroenterology 1997;112:A903.
  85. Scheib SA, Caldwell SH, Driscoll CJ, et al: Improvment in nutritional parameters and Child-Pugh class after TIPS for refractory ascites. Hepatology 1996;24:574A.

    External Resources

  86. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F: Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001;96:2442–2447.
  87. Lebrec D, Giuily N, Hadengue A, et al: Trans-jugular intrahepatic portosystemic shunts – comparison with paracentesis in patients with cirrhosis and refractory ascites – a randomized trial. J Hepatol 1996;25:135–144.
  88. Rössle M, Ochs A, Gülberg V, et al: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701–1707.
  89. Gines P, Uriz J, Calahorra B, et al: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839–1847.
  90. Sanyal AJ, Genning C, Reddy KR, et al: The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003;124:634–641.
  91. Salerno F, Merli M, Riggio O, et al: Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629–635.
  92. Rosemurgy AS, Zervos EE, Clark WC, et al: TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: A prospective randomized trial. Ann Surg 2004;239:883–889.
  93. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rössle M: Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001;13:529–534.
  94. Gordon FD, Anastopoulos HT, Crenshaw W, et al: The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366–1369.
  95. Nolte W, Figulla HR, Ringe B, et al: Refractory hydrothorax in primary biliary cirrhosis – successful treatment with a transjugular intrahepatic portosytemic stent shunt. Dtsch Med Wochenschr 1997;122:1275–1280.
  96. Petruff CA, Anastopoulos HT, Chopra S, McEniff N, Lewis WD: The successful use of TIPS for the treatment of symptomatic refractory hepatic hydrothorax: long-term follow up. Hepatology 1996;24:190A.
  97. Andrade RJ, Martin-Palanca A, Fraile JM, et al: Transjugular intrahepatic portosystemic shunt for the management of hepatic hydrothorax in the absence of ascites. J Clin Gastroenterol 1996;22:305–307.
  98. Strauss RM, Martin LG, Kaufman SL, Boyer TD: Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994;89:1520–1522.
  99. Haskal ZJ, Zuckerman J: Resolution of hepatic hydrothorax after transjugular intrahepatic portosystemic shunt (TIPS) placement. Chest 1994;106:1293–1295.
  100. Angeli P: Review article: prognosis of hepatorenal syndrome – has it changed with current practice? Aliment Pharmacol Ther 2004;20(suppl 3):44–46.
  101. Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55–64.
  102. Gines P, Guevara M, Perez-Villa F: Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 2004;40:16–18.
  103. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T: Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome [letter]. Lancet 1997;349:697–698.
  104. Cardenas A: The Budd-Chiari syndrome. N Engl J Med 2004;350:1906–1908.

    External Resources

  105. Ochs A, Sellinger M, Haag K, et al: Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol 1993;18:217–225.
  106. Peltzer MY, Ring EJ, LaBerge JM, Haskal ZJ, Radosevich PM, Gordon RL: Treatment of Budd-Chiari syndrome with a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol 1993;4:263–267.
  107. Rössle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D: The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004;135:394–403.
  108. Blokzijl H, de Knegt RJ: Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosytemic shunt. Hepatology 2002;35:1551–1552.
  109. Gasparini D, Del FM, Sponza M, et al: Transjugular intrahepatic portosystemic shunt by direct transcaval approach in patients with acute and hyperacute Budd-Chiari syndrome. Eur J Gastroenterol Hepatol 2002;14:567–571.
  110. Perello A, Garcia-Pagan JC, Gilabert R, et al: TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132–139.
  111. Blum U, Rössle M, Haag K, et al: Budd-Chiari Syndrome – technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology 1995;197:805–811.
  112. Hernandez-Guerra M, Turnes J, Rubinstein P, et al: PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004;40:1197–1202.
  113. Fried MW, Connaghan DG, Sharma S, et al: Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996;24:588–591.
  114. Zenz T, Rössle M, Bertz H, Siegerstetter V, Ochs A, Finke J: Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation – role of transjugular intrahepatic portosystemic shunt (TIPS). Liver 2001;21:31–36.
  115. Blum U, Haag K, Rössle M, et al: Noncavernomatous portal vein thrombosis in hepatic cirrhosis – treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. Radiology 1995;195:153–157.
  116. Bilbao JI, Elorz M, Vivas I, Martinez-Cuesta A, Bastarrika G, Benito A: Transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of venous symptomatic chronic portal thrombosis in non-cirrhotic patients. Cardiovasc Intervent Radiol 2004;27:474–480.
  117. Cherukuri R, Haskal ZJ, Naji A, Shaked A: Percutaneous thrombolysis and stent placement for the treatment of portal vein thrombosis after liver transplantation: long-term follow-up. Transplantation 1998;65:1124–1126.
  118. Selim KM, Akriviadis EA, Zuckerman E, Chen D, Reynolds TB: Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998;93:455–458.
  119. Allgaier HP, Haag K, Ochs A, et al: Hepato-pulmonary syndrome – successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 1995;23:102.
  120. Krowka MJ: Hepatopulmonary syndrome: what are we learning from interventional radiology, liver transplantation, and other disorders? Gastroenterology 1995;109:1009–1013.
  121. Burger JA, Ochs A, Wirth K, et al: The trans-jugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 1997;8:200–202.
  122. Gimson AE: Transjugular intrahepatic portosystemic stent-shunt and liver transplantation – how safe is the bridge? Eur J Gastroenterol Hepatol 2002;14:821–822.
  123. Tripathi D, Therapondos G, Redhead DN, Madhavan KK, Hayes PC: Transjugular intrahepatic portosystemic stent-shunt and its effects on orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2002;14:827–832.
  124. Maleux G, Pirenne J, Vaninbroukx J, Aerts R, Nevens F: Are TIPS stent-grafts a contraindication for future liver transplantation? Cardiovasc Intervent Radiol 2004;27:140–142.

 goto top of outline Author Contacts

Prof. Andreas Ochs, MD, MBA
Head of the Department of Internal Medicine, Evangelisches Diakonie Krankenhaus
Teaching Hospital of the Medical Faculty University of Freiburg
Wirthstrasse 11, D–79110 Freiburg (Germany)
Tel. +49 761 1301233, Fax +49 761 1301633, E-Mail andi.ox@t-online.de


 goto top of outline Article Information

Number of Print Pages : 9
Number of Figures : 2, Number of Tables : 3, Number of References : 124


 goto top of outline Publication Details

Digestive Diseases (State-of-the-Art Clinical Reviews)

Vol. 23, No. 1, Year 2005 (Cover Date: 2005)

Journal Editor: Malfertheiner, P. (Magdeburg)
ISSN: 0257–2753 (print), 1421–9875 (Online)

For additional information: http://www.karger.com/ddi


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.